These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16093999)

  • 1. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Berger RE
    J Urol; 2005 Sep; 174(3):941. PubMed ID: 16093999
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Ziaei S; Ninavaei M; Faghihzadeh S
    Acta Obstet Gynecol Scand; 2004 Oct; 83(10):909-11. PubMed ID: 15453884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
    Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
    J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users.
    Sereepapong W; Chotnopparatpattara P; Taneepanichskul S; Markham R; Russell P; Fraser IS
    Hum Reprod; 2004 Mar; 19(3):547-52. PubMed ID: 14998949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone mineral density and DMPA.
    Westhoff C
    J Reprod Med; 2002 Sep; 47(9 Suppl):795-9. PubMed ID: 12380409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%.
    Harel Z; Wolter K; Gold MA; Cromer B; Stager M; Johnson CC; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Burkman R; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Dec; 82(6):503-12. PubMed ID: 21074012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable contraception.
    Mishell DR
    J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
    [No Abstract]   [Full Text] [Related]  

  • 10. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic intracranial hypertension associated with depot medroxyprogesterone.
    Chan JW
    Eye (Lond); 2006 Dec; 20(12):1396-7. PubMed ID: 16440012
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate users.
    Chotnopparatpattara P; Taneepanichskul S; Treratanachat S; Charuruks N
    J Med Assoc Thai; 2003 Feb; 86(2):172-7. PubMed ID: 12678156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormones and weight change.
    Pelkman C
    J Reprod Med; 2002 Sep; 47(9 Suppl):791-4. PubMed ID: 12380408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal venous occlusion associated with depot medroxyprogesterone acetate.
    Deen BF; Shuler RK; Fekrat S
    Br J Ophthalmol; 2007 Sep; 91(9):1254. PubMed ID: 17709596
    [No Abstract]   [Full Text] [Related]  

  • 16. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RETIRED: Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa).
    Black A; ;
    J Obstet Gynaecol Can; 2006 Apr; 28(4):305-308. PubMed ID: 16776909
    [No Abstract]   [Full Text] [Related]  

  • 18. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
    Atrio J
    J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
    Beksinska ME; Rees HV
    Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormonal contraception using depot preparations].
    Keller PJ
    Ther Umsch; 1986 May; 43(5):395-9. PubMed ID: 2941890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.